This content is only available within our institutional offering.
17 Sep 2019
ROCHE: PharmaDay 2019: not transformative, but aimed at sharing confidence in the pipeline | BUY - Top Picks | CHF340(+25%)
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
ROCHE: PharmaDay 2019: not transformative, but aimed at sharing confidence in the pipeline | BUY - Top Picks | CHF340(+25%)
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
17 Sep 2019 -
Author:
Eric Le Berrigaud -
Pages:
4
ROCHE - BUY - Top Picks | CHF340(+25%)
PharmaDay 2019: not transformative, but aimed at sharing confidence in the pipeline
Behind images from the outside, a profound change in practices
Roche wants to remain a long-term play
A rich agenda over the next 18 months
We are introducing satralizumab to our sales model